Monday, May 31, 2021
10 serious COVID patients given Israeli drug, leave hospital in one day
A laboratory image shows a healthy lung, a sick lung and lung treated with MesenCure.
(photo credit: Courtesy)
An Israeli biotechnology company has claimed a 100% success rate in the first 10 patients treated with its drug as part of an early-stage clinical trial at Rambam Health Care Campus in Haifa.
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment